New Season. Same Threat.
How Will You Help Prevent More Flu?

Influenza season has arrived and Sanofi Pasteur is offering a new series of live educational video webcasts. Presented by subject-matter experts, these webcasts will:

  • Examine the medical burden of influenza and its economic impact in adults 50+ years of age
  • Explore how influenza can exacerbate chronic health conditions and lead to severe outcomes, such as hospitalization and death
  • Review pivotal efficacy and safety trials of Fluzone® High-Dose (Influenza Vaccine) and Flublok® Quadrivalent (Influenza Vaccine)

SCHEDULE

  EASTERN CENTRAL MOUNTAIN PACIFIC
Wednesday, November 14, 2018
Audrey M. Stevenson, PhD, MPH, MSN, FNP-BC
12:15 PM 11:15 AM 10:15 AM 9:15 AM
2:15 PM 1:15 PM 12:15 PM 11:15 AM
Thursday, November 15, 2018
Robert B. Belshe, MD
1:15 PM 12:15 PM 11:15 AM 10:15 AM
3:15 PM 2:15 PM 1:15 PM 12:15 PM

 


INDICATION FOR FLUBLOK QUADRIVALENT AND FLUZONE HIGH-DOSE VACCINES

Flublok Quadrivalent and Fluzone High-Dose vaccines are indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B virus(es) contained in each vaccine. Flublok Quadrivalent vaccine is approved for use in persons 18 years of age and older. Fluzone High-Dose vaccine is approved for use in persons 65 years of age and older.

IMPORTANT SAFETY INFORMATION FOR FLUBLOK QUADRIVALENT AND FLUZONE HIGH-DOSE VACCINES

Flublok Quadrivalent and Fluzone High-Dose vaccines should not be administered to anyone who has had a severe allergic reaction (eg, anaphylaxis) to any component (including egg protein for Fluzone High-Dose vaccine) or previous dose of the respective vaccine. In addition, Fluzone High-Dose vaccine should not be administered to anyone who has had a severe allergic reaction to a previous dose of any influenza vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Flublok Quadrivalent or Fluzone High-Dose vaccine should be based on careful consideration of the potential benefits and risks.

The most common local and systemic adverse reactions to Flublok Quadrivalent and Fluzone High-Dose vaccines include pain at the injection site; headache and myalgia. Other adverse reactions may occur. Vaccination with Flublok Quadrivalent or Fluzone High-Dose vaccine may not protect all individuals.

Before administration, please see the full Prescribing Information for Fluzone High-Dose vaccine and Flublok Quadrivalent vaccine.

To order Fluzone High-Dose or Flublok Quadrivalent vaccine, go to VaccineShoppe.com or call 1-800-VACCINE (1-800-822-2463).

Fluzone High-Dose and Fluzone vaccines are manufactured and distributed by Sanofi Pasteur Inc.

Fluzone High-Dose vaccine (CPT® code 90662) is a covered benefit under Medicare Part B.

Flublok Quadrivalent vaccine is manufactured by Protein Sciences Corporation, a Sanofi company, and distributed by Sanofi Pasteur Inc.

Flublok Quadrivalent vaccine (CPT code 90682) is a covered benefit under Medicare Part B.

Technical Support

If you have experienced issues with streaming audio/video, please contact the webcast support desk by calling 855-341-2395

Please note that live support will be available 30 minutes prior to your program start time.


Faculty

Audrey M. Stevenson, PhD, MPH, MSN, FNP-BC

Division Director of Family Health Services
Salt Lake County Health Department
Salt Lake City, Utah

Full Bio
Robert B. Belshe, MD

Dianna and J. Joseph Adorjan Endowed Professor of Infectious Diseases and Immunology Emeritus

Saint Louis University School of Medicine

St. Louis, Missouri

Full Bio